Stock Research for EPZM

EPZM

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

EPZM Stock Chart & Research Data

The EPZM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the EPZM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


EPZM Due diligence Resources & Stock Charts

The EPZM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View EPZM Detailed Price Forecast - CNN Money CNN View EPZM Detailed Summary - Google Finance
Yahoo View EPZM Detailed Summary - Yahoo! Finance Zacks View EPZM Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View EPZM Trends & Analysis - Trade-Ideas Barrons View EPZM Major Holders - Barrons
NASDAQ View EPZM Call Transcripts - NASDAQ Seeking View EPZM Breaking News & Analysis - Seeking Alpha
Spotlight View EPZM Annual Report - CompanySpotlight.com OTC Report View EPZM OTC Short Report - OTCShortReport.com
TradeKing View EPZM Fundamentals - TradeKing Charts View EPZM SEC Filings - Bar Chart
WSJ View Historical Prices for EPZM - The WSJ Morningstar View Performance/Total Return for EPZM - Morningstar
MarketWatch View the Analyst Estimates for EPZM - MarketWatch CNBC View the Earnings History for EPZM - CNBC
StockMarketWatch View the EPZM Earnings - StockMarketWatch MacroAxis View EPZM Buy or Sell Recommendations - MacroAxis
Bullish View the EPZM Bullish Patterns - American Bulls Short Pains View EPZM Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View EPZM Stock Mentions - StockTwits PennyStocks View EPZM Stock Mentions - PennyStockTweets
Twitter View EPZM Stock Mentions - Twitter Invest Hub View EPZM Investment Forum News - Investor Hub
Yahoo View EPZM Stock Mentions - Yahoo! Message Board Seeking Alpha View EPZM Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for EPZM - SECform4.com Insider Cow View Insider Transactions for EPZM - Insider Cow
CNBC View EPZM Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for EPZM - OTC Markets
Yahoo View Insider Transactions for EPZM - Yahoo! Finance NASDAQ View Institutional Holdings for EPZM - NASDAQ


Stock Charts

FinViz View EPZM Stock Insight & Charts - FinViz.com StockCharts View EPZM Investment Charts - StockCharts.com
BarChart View EPZM Stock Overview & Charts - BarChart Trading View View EPZM User Generated Charts - Trading View


Latest Financial News for EPZM

Why Is Epizyme (EPZM) Down 18% Since Its Last Earnings Report?
Posted on Thursday April 12, 2018

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.


Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up
Posted on Wednesday April 11, 2018

Epizyme (EPZM) publishes tazemetostat phase I clinical data in The Lancet Oncology. The study demonstrated favorable safety findings and anti-tumor activity.


Recent Analysis Shows Photronics, Just Energy Group, Baidu, Nomura Holdings Inc ADR, KT, and Epizyme Market Influences — Renewed Outlook, Key Drivers of Growth
Posted on Wednesday April 11, 2018

NEW YORK, April 11, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...


Epizyme Announces Publication of Tazemetostat Phase 1 Clinical Data in The Lancet Oncology
Posted on Monday April 09, 2018

CAMBRIDGE, Mass., April 09, 2018-- Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, announced today its first-in-human data on the effects of EZH2 inhibition in patients with ...


Enter a stock symbol to view the stock details.